BLOG

Clinical-trials-arena

Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023

Cerevance is targeting these fluctuations with a planned Phase II/III trial of its investigational compound CVN424, CMO Jordan Dubow says. The Boston-based biotech plans to initiate the study in the first quarter of 2023, testing CVN424 as an adjunctive therapy to levodopa, he adds.